Skip To Main Content
Jingying Lan on Muck Rack

Jingying Lan

As seen in: Arthritis Research & Therapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jingying

Contact Jingying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A non-invasive model for diagnosis of primary Sjogren’s disease based on salivary biomarkers, serum autoantibodies, and Schirmer’s test - Arthritis Research & Therapy

|
By Xinwei Zhang, Huiqin Lu, Aodi Wang, Yingying Shi, Qi Zhang, YING WANG, Jingying Lan, Chubing Chen, Chaoqiong Deng, Lingyu Liu, Hongyan Qian, Zhangdi Liao, Yangchun Chen, Wuwei Zhuang
| Arthritis Research & Therapy Verified
This study was designed to identify non-invasive markers that could help diagnose pSjD. A total of 258 inpatients from the Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital of Xiamen University between January 2021 and August 2022 were selected in our study. All of them were suspected pSjD patients when first admitted into the hospital and have been performed MSG biopsies which is a critical inspection for the classification of pSjD.
Open in Who Shared Issue with article?

Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis - Arthritis Research & Therapy

|
By Hongyan Qian, Shiju Chen, Xinwei Zhang, Aodi Wang, Guixiu Shi, Yuan Liu, Chaoqiong Deng, Jingying Lan
| Arthritis Research & Therapy Verified
Direct depletion of pathogenic FLS subsets by targeting cell surface markers with antibodies, chimeric antigen receptor (CAR)-T cells or vaccines might be the most effective way to target pathogenic FLSs in RA. Among these FLS cell surface markers, CDH-11 first attracted attention as a promising target for RA treatment. However, a phase II trial of monoclonal antibodies targeting CDH-11 (RG6125) in RA patients was discontinued in 2018 due to a lack of efficacy [43].
Open in Who Shared Issue with article?
See all 2 articles